Details of the Drug
General Information of Drug (ID: DMF08UT)
Drug Name |
6,7-Dihydroxy-2-phenyl-chromen-4-one
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
6,7-dihydroxyflavone; 38183-04-9; 6,7-dihydroxy-2-phenyl-4H-chromen-4-one; 6,7-Dihydroxy-2-phenyl-chromen-4-one; 6,7-dihydroxy flavone; 4H-1-Benzopyran-4-one, 6,7-dihydroxy-2-phenyl-; CHEMBL300814; 6,7-dihydroxy-2-phenylchromen-4-one; SR-05000002250; PubChem9843; 6,7 - Dihydroxyflavone; AC1NS43N; SPECTRUM1500718; SCHEMBL980197; DivK1c_000421; CTK4H9455; KBio1_000421; HMS501F03; DTXSID60191569; NINDS_000421; GSAOUZGPXSGVRS-UHFFFAOYSA-N; ZINC3871176; BDBM50077318; AKOS024283483; CCG-208431; MCULE-6698063887; IDI1_000421; ACM38183049
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 254.24 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.3 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||